Friday 6 November 2026 Export BLCO’s income statement to Excel — free account

Bausch + Lomb Corporation

BLCO Healthcare Medical Instruments & Supplies

Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.

Revenue: +7.34%
EPS: +222.4%
Free cash flow: +182.5%
Total debt: +2.93%

Quarter to September 2026, against a year earlier

19.94 0.66 −3.20%

Follow BLCO

Alert me

Market cap: $7.1B
P/E: 0.0×
Fwd P/E: 749×
Dividend yield: —
F-score: 3/9
Altman Z: 0.87
Beneish M: −2.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bausch + Lomb Corporation (BLCO) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2022: revenue by segment, and margins
Vision Care	2,369	62.87%
Surgical	718	19.06%
Pharmaceuticals	681	18.07%
Gross margin		59.69%
Operating margin		5.49%
Pre-tax margin		1.94%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Other revenues	21 0.41%	17 0.35%	15 0.36%	22 0.58%	28 0.74%	31 0.91%
Also reported: a second breakdown of the same revenue
Devices	1,922 37.68%	1,800 37.57%	1,650 39.80%	1,572 41.72%	1,596 42.39%	1,314 38.51%
OTC	1,834 35.95%	1,724 35.98%	1,611 38.86%	1,461 38.77%	1,394 37.03%	1,310 38.39%
Pharmaceuticals	1,081 21.19%	969 20.23%	618 14.91%	468 12.42%	493 13.09%	508 14.89%
Branded and Other Generics	243 4.76%	281 5.87%	252 6.08%	245 6.50%	254 6.75%	249 7.30%
Other revenues	21 0.41%	17 0.35%	15 0.36%	22 0.58%	28 0.74%	31 0.91%
Product sales	5,080	4,774	4,131	—	—	—
Revenue	5,101	4,791	4,146	3,768	3,765	3,412

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Product sales	‡	‡	‡	‡	‡	‡
Other revenues	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Vision Care	2,923 57.30%	2,739 57.17%	2,543 61.34%	2,369 62.87%	2,327 61.81%	2,109 61.81%
Pharmaceuticals	1,284 25.17%	1,209 25.23%	836 20.16%	681 18.07%	720 19.12%	726 21.28%
Surgical	894 17.53%	843 17.60%	767 18.50%	718 19.06%	718 19.07%	577 16.91%
Revenue	5,101	4,791	4,146	3,768	3,765	3,412

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Vision Care	‡	‡	‡	‡	‡	‡
Pharmaceuticals	‡	‡	‡	‡	‡	‡
Surgical	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021
U.S. and Puerto Rico	2,546 49.91%	2,413 50.37%	1,934 46.65%	1,695 44.98%	1,618 42.97%
Other	777 15.23%	712 14.86%	655 15.80%	616 16.35%	572 15.19%
China	358 7.02%	358 7.47%	344 8.30%	343 9.10%	390 10.36%
France	246 4.82%	227 4.74%	210 5.07%	195 5.18%	201 5.34%
Japan	186 3.65%	180 3.76%	187 4.51%	192 5.10%	224 5.95%
Germany	164 3.22%	152 3.17%	147 3.55%	138 3.66%	149 3.96%
Russia	148 2.90%	120 2.50%	106 2.56%	132 3.50%	116 3.08%
United Kingdom	137 2.69%	132 2.76%	121 2.92%	108 2.87%	111 2.95%
Canada	135 2.65%	127 2.65%	110 2.65%	101 2.68%	101 2.68%
Italy	102 2.00%	91 1.90%	82 1.98%	72 1.91%	75 1.99%
Spain	101 1.98%	92 1.92%	85 2.05%	77 2.04%	80 2.12%
Mexico	75 1.47%	75 1.57%	68 1.64%	55 1.46%	40 1.06%
Poland	75 1.47%	65 1.36%	51 1.23%	44 1.17%	42 1.12%
South Korea	51 1.00%	47 0.98%	46 1.11%	—	46 1.22%
Revenue	5,101	4,791	4,146	3,768	3,765

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.